Aricept 30-week, Phase III trialsADAS-cog Results
US Study† Multinational Study‡
ITT-LOCF analysis; **p?0.001 for Aricept versus placebo
†Rogers et al. Neurology 1998;50:136–145; ‡Burns et al. Dement Geriatr Cogn Disord 1999;10:237–244
Least squares mean change frombaseline (±SE)